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Abstract
Agitated and aggressive behaviours are common in theBackground: 
psychiatric setting and rapid tranquilisation is sometimes unavoidable. A
survey of Lebanese practice has shown that an intramuscular haloperidol,
promethazine and chlorpromazine combination is a preferred form of
treatment but there are no randomised trials of this triple therapy.
 This is a pragmatic randomised trial. Setting - the psychiatricMethods:
wards of the Psychiatric Hospital of the Cross, Jal Eddib, Lebanon.
Participants - any adult patient in the hospital who displays an aggressive
episode for whom rapid tranquilisation is unavoidable, who has not been
randomised before, for whom there are no known contraindications.
Randomisation – stratified (by ward) randomisation and concealed in
closed opaque envelope by independent parties. Procedure – if the clinical
situation arises requiring rapid tranquilisation, medical residents overseeing
the patient will open a TREC-Lebanon envelope in which will be notification
of which group of treatments should be preferred [Haloperidol +
Promethazine + Chlorpromazine (HPC) or Haloperidol + Promethazine
(HP)], along with forms for primary, secondary and serious adverse effects.
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 (HP)], along with forms for primary, secondary and serious adverse effects.
Treatment is not given blindly. Outcome - primary outcome is calm or
tranquil at 20 minutes post intervention. Secondary outcomes are
calm/tranquil at 40, 60 and 120 minutes post intervention, asleep, adverse
effects, use of straitjacket and leaving the ward. Follow-up will be up to two
weeks post randomisation.
Findings from this study will compare the HPC versus HPDiscussion: 
combination used in Lebanon’s psychiatry emergency routine practice.
ClinicalTrials.gov  . Registration date,Trial registration: NCT03639558
August 21, 2018.
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Abbreviations
HPC: Haloperidol + Promethazine + Chlorpromazine; HP: 
Haloperidol + Promethazine; TREC: Abbreviation for the 
Portuguese ‘Tranquilização Rápida-Ensaio Clínico’ or Rapid 
Tranquilisation Clinical Trial; RT: Rapid Tranquilisation; ER: 
Emergency Room; DMC: Data Monitoring Committee; SC: 
Steering Committee 
Introduction
Aggressive and violent behaviour is a common behaviour 
seen in emergency psychiatric presentations with a preva-
lence of 3–10%1. This aggression is due to a range of psychiat-
ric disorders, such as schizophrenia and bipolar disorder, and/or 
substance use, personality disorders or dementia2. Guidelines 
recommend aggressive patients to be ‘verbally tranquilised’ or 
some form of de-escalation in order for the attending physician 
to accurately and safely perform a diagnostic history and physical 
examination3. Aggressive patients make this process diffi-
cult or sometimes impossible and carers may be required to 
work with limited evidence. Since the psychiatric team has a 
responsibility of ensuring the safety of everyone, rapid and safe 
tranquilisation may become unavoidable.
Rapid tranquillisation
Rapid tranquillisation (RT) is not a ‘treatment’ but rather a 
short-term management technique for severely agitated and/or 
aggressive behaviour in people experiencing severe psychiat-
ric distress. Due to its restrictive nature, RT is a last resort when 
all other attempts to calm a situation have failed and should 
always be used in a way that respects human rights and never 
as a substitute for adequate staffing4.
In this difficult situation medication(s) are most commonly admin-
istered intramuscularly5, and, depending on where in the world 
the management is happening, physical restraints may include 
use of a straitjacket6, seclusion room7 or medical restraints8 - 
binding the patient safely to a bed using two or four points9. 
Physical restraining by staff to administer medication is common 
worldwide.
Guidelines
Globally, guidelines differ in their specific recommendations4,10,11 
– often based on the same limited evidence - and then may not be 
adhered to in local clinical practice12,13. There are no directly rel-
evant national Lebanese guidelines.
Local practice
In preparation for this study we surveyed RT practice in the larg-
est (>800 beds) psychiatric hospital in Lebanon (Psychiatric 
Hospital of the Cross, Beirut). Several different medications 
were used but the use of a combination of haloperidol plus 
promethazine plus chlorpromazine (HPC) was common13. 
Haloperidol plus promethazine (HP) – without the addition of 
chlorpromazine - was also used. Long clinical experience has 
proved both combinations effective, but which is best in terms 
of overall safety remains unclear.
Existing evidence
Our systematic searches found that the HPC combination is 
used elsewhere14 but identified no relevant randomised trials. 
The HP combination, however, has strong trial-based evidence 
from low and middle-income countries supporting its use 
- albeit in comparison with medications other than HPC15. 
There is an unanswered question as regards the relative effects of 
HPC versus HP.
TREC-Lebanon
This study takes its name from the first Brazilian TREC 
study (TREC – abbreviation for the Portuguese ‘Tranquiliza-
ção Rápida-Ensaio Clínico’ or Rapid Tranquilisation Clinical 
Trial)16,17 indicating the debt we owe to their pragmatic design 
and to allow easy identification with an increasing group of 
related randomised trials.
Objective
TREC-Lebanon aims to compare its routine emergency drug 
HPC versus HP during an agitated episode requiring rapid 
tranquilisation.
SPIRIT checklist
The SPIRIT 2013 statement which consists of a 33 item check-
list of minimum recommended items18. More information can be 
found on the SPIRIT website (Table 1).
Setting
Lebanon is a low to middle income country in the Middle-East 
with a population of approximately 6 million19. The country 
has three mental hospitals and five psychiatric units within gen-
eral hospitals (43 psychiatric beds per 10,000; 1 psychiatrist 
per 100,000)20. The Lebanese Ministry of Health contracts the 
private sector to provide free treatment for patients who 
cannot afford to pay (the majority)20. There are no disability 
benefits for people with mental disorders and no disability 
funding for mental health21. Psychiatric Hospital of the Cross, set 
in the metropolitan area of Beirut (>2 million people), provides a 
service that extends across the whole country.
Methods
TREC-Lebanon is a pragmatic trial designed by the main 
researcher (JD) working in close collaboration with partners in the 
Psychiatric Hospital of the Cross, Jal Eddib, Lebanon. 
This is the final version of the protocol.
Eligibility
Inclusion criteria. An adult (18–64 years) will be eligible if, 
when presenting at the Psychiatric Hospital of the Cross:
i.    he/she requires emergency acute intramuscular medi-
cation because of disturbed and dangerous behaviour 
thought due to psychiatric morbidity; and
ii.    if the clinician is uncertain of the benefits of the HPC 
combination over those of HP used together.
Exclusion criteria. A person will not be eligible if:
i. The clinician
•    knows one treatment regimen has benefit over the 
other for that particular person;
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•    is aware of a contra-indication of one of the 
treatments, such as
■   allergy;
■   past adverse reaction; or
■    already given/taken drugs in the community which 
would make additional HP or HPC ill-advised;
•    does not want to enter the person into the trial for any 
reason
ii.    There is an Advanced Directive expressing a wish for 
one or other, or another treatment in the emergency 
setting;
iii.    The person has already been randomised into the trial; 
and if
iv.    An accompanying person (friend/family/Police Officer) 
refuses patient trial entry.
Interventions
Haloperidol, promethazine and chlorpromazine are included in 
the WHO’s List of Essential Drugs22.
Chlorpromazine. Chlorpromazine is a widely used23, effective24 
antipsychotic drug, but can cause a number of adverse 
effects including anticholinergic and antihistaminic effects25. 
Chlorpromazine is known to be the most epileptogenic of the 
older antipsychotic drugs causing seizures ranging from 1–4% 
depending on dosages26.
Haloperidol. Haloperidol is also an older effective27 antipsy-
chotic, less prone than chlorpromazine to cause sedation (less 
antihistaminic effects) but more causative of movement disorders 
including acute dystonia (involuntary dramatic contractions of 
muscles in, for example, the neck, face, pelvis, spinal muscles)28. 
These acute reactions are not life-threatening but are distress-
ing and frightening to the patient, further eroding trust in the 
services. Acute dystonia can be swiftly and successfully treated 
with drugs with anticholinergic/antihistaminic properties, such as 
promethazine or procyclidine29,30. The occurrence of these 
reactions, in 1–2% of those given haloperidol alone, was the 
cause of the early termination of the second TREC trial of Brazil 
(comparing HP with haloperidol alone)31. The Steering Group 
of that study felt the evidence was strong enough to make the 
sole emergency use of intramuscular haloperidol impossible to 
justify if promethazine was available.
Promethazine. Promethazine hydrochloride is also an old antip-
sychotic drug but also has potent anticholinergic and antihis-
taminic properties. This helps offset sickness and movement 
disorders – including acute dystonia – but also causes it to be 
sedative32.
The combinations. Combining drugs can change - increase or 
decrease - the incidence of known adverse effects33 or result 
in novel effects unheard of with each drug on its own34,35. The 
Table 1. SPIRIT Checklist (TREC-Lebanon).
STUDY PERIOD
Enrolment Allocation Post-allocation Close-out
TIMEPOINT** -t1 0 t1 t2 t3 t4 tx
ENROLMENT: X 20 MINUTES 40 MINUTES 60 MINUTES 120 MINUTES 2 weeks
Eligibility screen X
Informed consent X
[List other procedures] X
Allocation X
[Intervention A] Haloperidol + Promethazine X X X X X
[Intervention B] Haloperidol + Promethazine 
+ Chlorpromazine
X X X X X
ASSESSMENTS:
Aggression X X X X X X
Tranquillity X X X X X
     Demographics X X
     Adverse effects X X X X
     Sleep X X X X
Straitjacket X X X X
Left the ward X X X X X X X
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HP combination is well tested, widely used and trusted. Evidence-
based guidelines now recommend its use36. We think the triple 
combination of haloperidol, promethazine and chlorpromazine 
(HPC) is not so widely employed, but do know it is not only 
Lebanon that uses it 17. Whether addition of another drug (chlo-
rpromazine) has benefit or causes difficulties may be illustrated 
by this study, but we identified no existing literature suggesting 
that there are particular concerns regarding adverse effects of this 
HPC combination.
Sample size and statistical considerations
The primary aim of TREC-Lebanon is to investigate whether 
the proportion of patients calm/tranquil at 20 minutes is any 
different between the two investigative approaches. In such a 
stressful situation, a small advantage for an intervention could 
represent a worthwhile benefit. However, to highlight a clear 
difference with confidence, this would need larger numbers of 
people than this phase of work would allow (Table 2). Realisti-
cally, taking into account our preliminary work13 and the time 
constraints of this PhD project with no extramural funding, 
TREC-Lebanon expects to involve a minimum of 90 patients 
across a 3-month period. Confidence intervals will be calculated 
and interpreted according to Altman37. Statistical significance 
at the 5% level for the primary outcome and at 1% for the 
secondary outcomes. K statistics will be used for estimating 
inter-rater agreement for the primary outcome. SPSS version 
24 will be used for the analysis of statistical data. 
Randomisation
Randomisation will be undertaken in the United Kingdom (by 
CEA). Small block sizes were chosen to ensure even distribu-
tion of treatments (4,6) and whether HPC was to be coded as ‘1’ 
or ‘0’ was randomly assigned using MS Excel’s RAND function 
(HPC coded as ‘1’). A free online programme randomised block 
size, and then treatments to groups within blocks. Using our 
survey data13, it was thought that 30% of randomised incidents 
would be on the women’s ward - so the first set of complete 
blocks covering this proportion (therefore up to #32) 
were taken for the women’s ward and men were then started at 
number 33. Tables of TREC-Envelopes’ number by contents 
will be constructed and supplied to a Lebanese colleague (SH). 
The tables will list the contents of the envelopes in groups of 
ten, not disclosing the block sizes used. SH, always working 
independently of both the TREC-Lebanon team and CEA, will 
ensure that the correct medication combination is named within 
each TREC-envelope before it is sealed.
Concealment of allocation will be ensured by i) not disclos-
ing the randomly varied block sizes to the colleagues pack-
ing the envelopes; ii) the supply of tables to those colleagues 
that gives no suggestion that blocks are even being employed; 
iii) the independence of those packing the envelopes from the 
other researchers or the clinicians; and iv) the identical nature 
of the packed fully opaque envelopes.
These easy-to-use envelopes will be constructed of card-
board, identical and consecutively numbered. The final check 
to ensure that nothing has gone wrong with the randomisation 
will be by the Principal Investigator (CH) filling in a form for 
each block of ten opened envelopes. At analysis the date and 
time of instigation of treatment will be ordered and this 
will order the TREC-IDs showing that each envelope was 
opened consecutively.
TREC-Lebanon is blinded for the initial ratings only
Because the TREC-Lebanon study evaluates care in the emer-
gency situation, it is imperative that the doctors and nurses 
know which intervention is being given. The study is blind 
only up until the time that the TREC-Lebanon trial envelope is 
opened. Therefore, it is crucial that the evaluation of the sever-
ity of a person’s disturbance and the first impression on the 
possible cause for the disturbed behaviour are recorded 
before the envelope is opened. Once the envelope is opened, 
doctors and nurses will have knowledge of the medications 
to be used. It is perfectly feasible that the knowledge that one 
drug has been given will influence the care beyond the actual 
effects of the medication. Keeping the study open from that 
point onwards is not only practical in the emergency situation, 
but also desirable as the evaluation of care being undertaken 
is as near real-world circumstances as is possible.
Protocol registration
This trial has been registered and accepted at clinicaltrials.gov: 
https://clinicaltrials.gov/ct2/show/NCT03639558 (registered pro-
spectively on August 21, 2018).
Procedures
Pragmatism
All trial materials, and guidelines for their use, are provided in 
the TREC-Lebanon folder supplied by the co-ordinating cen-
tre. The TREC-Lebanon trial is designed to not interfere with 
routine care. The eligibility criteria are simple and the process 
of randomisation fits closely into normal hospital procedures. 
Data collection will be limited to the minimum necessary and 
will involve little more than extraction of routine information 
by a person designated to spend time on the TREC-Lebanon 
trial. No data are redundant. It is not envisaged that busy doctors 
and nurses will spend time filling out complicated forms.
Blinding raters would have added additional complexity to the 
study that would have made the trial much less acceptable to 
Table 2. Size and statistical considerations.
Haloperidol + Promethazine 
(% tranquilised)
Total N required by % 
difference
10% 15 % 20% 25%
5 280 150 98 70
10 124 86
15 98
20 108
25 116
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the emergency room (ER) staff. More importantly, it would 
have completely changed the emphasis of TREC-Lebanon. 
What is being evaluated is the real-world practice of giving two 
different drug regimens in the psychiatric emergency setting. 
In the real-world situation health care professionals know what 
treatment is being given.
In the community
Occasionally patients are given sedative medication by their 
parents, friends or law officials prior to psychiatric admission13. 
As far as the hospital clinician is concerned, he or she still 
decides if the patient should be randomised within the trial if 
the patient is still exhibiting an agitated episode.
Arrival at the hospital
Most people arrive at the hospital’s administrative centre 
whereby they are registered and then transferred to their ward13. 
If patients are presenting with violent conduct that could poten-
tially harm people in their vicinity, they are taken directly to 
their ward while those who brought them in fill out their paperwork 
– including all necessary consent forms (see section below).
Triage to randomisation
Unlike TREC-Rio17 whereby agitated patients arriving at 
the psychiatry ER have been given an intervention after the 
nurse opens the box within the ER, TREC-Lebanon oper-
ates differently due to the hospital not having an ER, prompt-
ing a different approach. The TREC-Envelopes are placed in the 
underground research clinic accessible only to research-
ers and doctors. The envelopes are separated between men 
and women (stratified randomisation). Residents who are on 
duty will be granted access to the research director’s clinic 
where the envelopes are securely kept and will be given two 
envelopes in a consecutive manner – one for a man and one 
for a woman while the research assistant keeps track and 
notes which envelopes have been taken. The resident carries 
the envelope during duty and in the event of an agitated 
episode, opens the envelope depending on sex, fills out the 
form, returns all forms within the envelope and returns it back 
to the research director’s clinic whereby completed forms 
will be stored in a separated secured TREC-box.
Whenever possible, carers accompanying the patient should have 
an opportunity to see the information leaflet (Extended data: 
TREC-Lebanon information for relatives) before randomisation.
If the attending doctor decides the person should not be 
entered into TREC-Lebanon, he/she will notify the resident on 
duty and anonymised information on this group will be collected:
•   date and time
•   age
•   gender
•   ethnicity (if applicable)
•    the reason not eligible for trial participation, or if they 
are eligible but failed to be randomised.
If the attending clinician decides the pateint to be eligible, 
then the next consecutive envelope is taken from the research 
director’s clinic, the form on its cover is filled out, and only 
then is it opened. The trial entry form printed on the sealed 
envelope (Extended data: TREC-Envelope entry form) records 
brief baseline details about the person, the severity of distur-
bance, its presumed cause, the date and time of opening and the 
name of the doctor. This action constitutes trial entry (Figure 1).
Residents
The residents for the trial are WHI, HEY, EA and TJM. The 
hospital undergoes frequent resident rotation; therefore, resi-
dents undergoing training within the hospital for long durations 
of time were recruited in order to begin the trial, train incoming 
residents and see the trial completed. All residents, the Research 
Director (SH) and the Principle Investigator (CH) are involved 
in a WhatsApp group chat to inform, keep track and ask 
questions should they arise during the course of the trial.
Trial envelopes
Every envelope has the entry form printed on it. Randomisa-
tion proceeds using a local pack system with the trial team 
providing the identical sealed envelopes made of sturdy fully 
opaque card.
Each envelope contains:
•    Paper slip indicating the use of Haloperidol + Promethazine 
(HP)
•    1 × TREC-Lebanon follow-up form (Extended data: 
Primary measures of outcome form)
•    2 × TREC-Lebanon stickers for the drug prescription form 
and medical notes
Or
•    Paper slip indicating the use of Haloperidol + Promethazine 
+ Chlorpromazine (HPC)
•    1 × TREC-Lebanon follow-up forms (Extended data: 
Primary measures of outcome form, Dr. Stopwatch form 
and TREC-Lebanon main data collection form)
•    2 × TREC-Lebanon stickers for the drug prescription 
form and medical notes
All doses used are at the discretion of the attending clinician. If 
the contents of a trial envelope are destroyed, or unfit for use, 
the person should not be randomised a second time and the 
equivalent material should be obtained from the usual hospital 
supplies.
In the event of continuing aggression despite the TREC- 
Lebanon medication, ongoing emergency management is entirely 
at the discretion of the clinicians; another envelope is not opened.
Outcome and follow-up
It is crucial that follow-up is complete and accurate for 
everyone entered into the study. As a pragmatic study, causing 
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Figure 1. Flow diagram.
Patient presenting with acute agitation or aggression
All measures taken attempting to calm the individual
such as de-escalation measures failed
Does patient fit
inclusion criteria?
No Do not
randomise
Yes
Fill TREC Envelope
(Randomise)
HPC HP
Time to tranquilisation: calm/lightly sedated.
Over sedation: Asleep
Over sedation: Asleep
Further RT doses are needed
Serious specific adverse effects and non-serious
general adverse events.
Need for restraint/seclusion
Need for restraint/seclusion
Calm/lightly sedated
Adverse effects: Any
Serious adverse effects
Additional tranquilising drugs
Doctor called to see patient
Accepting oral medication
No other episodes of aggression.
Doctor not called to see patient because of
aggression.
Accepted oral medication.
Discharged.
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minimal interference with routine care, TREC will not employ 
any rating scale outcomes. It is likely that completion of scales 
would be inaccurate and incomplete, validity and reliability 
would be in question and clinical utility problematic. The main 
outcome of TREC-Lebanon is tranquillisation by 20 minutes. 
This was the primary outcome requested by the nursing and 
medical staff of the hospital13. By asking the relevant clinical 
staff to select the primary outcome for TREC-Lebanon we 
hoped to ensure maximum compliance with the trial proto-
col. Therefore, upon injection of the patient, a timer is started 
on the resident’s phone and this rings at 20 minutes and then 
again at 40, 60 and 120 minutes. At each period the attending 
resident rates whether the person, in their opinion, is tranquil, 
asleep, has shown adverse effects or needs additional treatment 
and records this on the follow-up form found originally within 
the sealed envelope (Extended data: Primary measures of 
outcome form). The person is considered tranquillised when 
they are felt to be calm and peaceful, but not asleep. They 
should not be agitated or restless, nor displaying threatening 
verbal behaviour, physical aggression against objects, self- 
aggression or physical aggression to other people.
The Dr. Stopwatch form (Extended data) is included within 
the envelope and contains two boxes: time the resident felt the 
patient was tranquilised either tranquil or asleep and a comments 
box. The tranquilised box is the ‘true tranquilisation’ outside 
the 20, 40, 60 and 2 hour time intervals within the primary 
measure of outcome form, assuming the patient becomes 
tranquilised after the 2 hour maximum limit. The additional 
comments box is included if the resident needs to note addi-
tional information (i.e. why the patient did not calm down 
within the 2 hour time frame). The resident starts their own 
personal stopwatch from the time of intervention to when 
he/she feels the patient has become calm/tranquil or asleep.
Additional data are recorded at 24 hours and finally at two weeks 
(Extended data: TREC-Lebanon main data collection form). 
These additional data are to be extracted from routine notes. If 
the patient is transferred to another hospital, the co-ordinating 
centre will contact every relevant hospital to find out further 
details on what happened after transfer.
Data collection, entry and analysis
All data for TREC-Lebanon will be transcribed and collated 
from the TREC-envelope forms, the follow-up form, severe 
adverse event form and routine notes of each ER or ward into 
a form within MS Access – a database management system 
from Microsoft (Extended data: TREC-Lebanon main data 
collection form). These anonymised data, in compliance with 
the ethics committee requests, will be protected as the hard 
copy forms do not leave the research director’s clinic. All 
transcribed raw data used by the main researcher (JD) will have 
personal information such as names of patients abbreviated 
to retain anonymity.
Analysis will take place using Statistical Package for 
Social Sciences (SPSS)38. This will take the form of simple 
frequencies – to test the integrity of the data, and, for binary 
outcomes, relative risks and respective 95% confidence inter-
vals, and for continuous data mean differences and their 95% 
confidence intervals. Tables for this analysis are prepared before 
recruitment of the first patient (Extended data: Dummy 
statistical tables). No additional analyses are anticipated. All 
analysis will be based on groups as randomly allocated; this will 
be an intention-to-treat analysis.
All data that includes private information will be anonymised. 
Once the study is completed, access to raw data contain-
ing personal patient information will only be accessible to the 
hospitals’ director and responsible clinician.
Anticipated risks
Ineligible people entering the study
It is possible though highly improbable that patients who do not 
fit the trial’s entry criteria may enter the study. Those that do will 
not be counted as part of the trial and their notes will be disre-
garded. Detecting ineligible patients will be seen in the data 
entry form left in a bin on each ward (the TREC-bin into which 
all filled out envelopes are put) making it simple and direct to 
trace. 
Staff compliance with protocol
Attending resident and nurse should monitor action of given 
intervention, i.e. make sure given treatment has been injected 
properly. In the event that an agitated patient may break any 
of the treatment tools – mainly the syringe containing the treat-
ment intervention or destroy the vial containing the intervention 
before being placed within the syringe, another TREC envelope 
should not be opened. Instead, attending resident should carry 
on as per hospital protocol and fill out the serious event form 
detailing the circumstances (Extended data: Serious event 
form). Nurses should also detail the nature of compliance as 
they would normally do in their notes. In the event a patient 
does break the syringe or capsule, the situation is rectified with 
the nurse bringing the emergency treatment as detailed in the 
paper slip in the envelope.
Feasibility phase
A feasibility phase will take place before the trial commences. 
The feasibility phase will include a limited number of enve-
lopes (i.e. 5) with contents known to the trialists. The feasibil-
ity phase is designed to test the trial’s procedure in practice 
in order to assess if any unforeseen circumstances arise. In 
the event such unforeseen circumstances do arise, the trialists 
will rectify and mediate in the most practical way possible. 
Changes will be noted by the main researcher (JD) and updated 
in the trial protocol.
Toxicity and serious unexpected events
After trial entry, clinical events are recorded, as usual, in the 
patients’ notes. Complications and adverse events should be 
managed as usual. A serious unexpected event form (Extended 
data: Serious event form) is provided and will be sent to the 
TREC-Lebanon Co-ordinator (JD) as soon as it is completed.
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Ethics approval and consent to participate
The Helsinki Declaration39, the European Directive on Clini-
cal Trials40 and the Nuffield Council documents on bioethics41 
state that trials in non-consenting patients are permitted on two 
conditions: i) no other context exists in which to answer the 
question; and ii) all trial participants receive clear therapeutic 
benefit from whichever arm they are randomised to. Consideration 
also has to be given to the local legislation21, namely:
1.    Lebanese Act no. 72-9/9/1984 Welfare Act and Protection 
and Treatment of Mentally Ill Patients;
2.    Lebanese Act no. 673-16/3/1998 Narcotic Drugs and 
Psychotropic Substances and Precursors;
3.    Lebanese Act no. 220-29/5/2000 Rights of Mentally 
Handicapped in Lebanon; and
4.    Lebanese Act no 574-11/2/2004 Patients’ Rights and 
Informed Consent;
which also protects the rights of patients and their families and 
carers.
Aggressive patients in a situation of psychiatric emergency 
are not able to give consent for their participation in a study42 
as their aggressive state, along with their psychiatric disor-
der places them in a state whereby they lack the capacity to do 
so, e.g. a patient with schizophrenia suffering from hallucina-
tions is in a state where he or she is not mentally competent to 
understand the conditions of the treatments involved43. In the case 
where parents or legal guardians are unavailable, a third party 
must confirm to the best interest standard whereby the deci-
sion made is the most beneficial to the patient. This is a direct 
application of the principle of beneficence and proportionality: 
maximize benefit and avoidance of harm. The substituted 
judgment standard aims to implement the subjective preferences 
of the patient44.
In routine care medication is usually given against the will of 
the patient. Therefore, for TREC-Lebanon, in the same way that 
doctors are responsible for the choice of a treatment in routine 
care, they take responsibility for the recruitment of a patient 
into the study. TREC-Lebanon will not involve administer-
ing an inactive compound to those who clearly need sedation/ 
tranquillisation. Both treatments calm aggressive disturbed 
people13, so there is no ‘experimental’ intervention. What is 
still uncertain is the speed for the onset of action, the dura-
tion of the effects and the different kinds of adverse reactions. 
TREC-Lebanon will attempt to answer clinical questions to 
help the care of this group of people.
A patient/carer information leaflet about TREC-Lebanon 
is available for all for whom a TREC-Lebanon envelope is 
opened (in English and Lebanese Arabic). Carers will always 
be free to decide that their relative should not be entered. Not 
being involved in TREC-Lebanon will not affect the person’s 
standard of care. An information sheet is provided detailing the 
aim and purpose of the study (Extended data: TREC-Lebanon 
information for relatives).
Patients who do not have parents or legal guardians will still be 
randomised if they are aggressive and fit the inclusion crite-
ria, but will be given a patient consent form post randomisation 
detailing the background of the study and their right to withdraw 
all personal data from the trial for whatever reason they see 
fit (Extended data: TREC-Lebanon consent form for patients)
Ethics Application File from the Hospital of the Cross was 
filled out by the trial coordinator detailing the background and 
procedure of the trial (non-consenting nature, data sharing 
agreement, liability waiver) were read and signed before gaining 
ethical approval and IRB letter.
TREC-Lebanon did not require ethics approval from the Univer-
sity of Nottingham (Ethics number: 271) and has passed ethics 
approval from the Psychiatric Hospital of the Cross, Beirut, 
Lebanon (Ethics number: HPC 001/2018).
The Helsinki Declaration
The Declaration of Helsinki45 requires the informed consent 
of participants in randomized controlled trials (paragraph 25). 
However, according to paragraph 28, if the individual for what-
ever reason is unable to provide consent, a legally authorised 
individual – usually a family member or guardian may provide 
on behalf. Finally, paragraph 30 states if no family members 
are present and the research is unable to be delayed, randomi-
sation may proceed provided the specific reasons to why the 
patient is unable to provide consent (in this case, mental illness 
with violent display) and the research has been approved by 
an ethics committee. TREC-Lebanon abides by the Helsinki 
Declaration and provides a consent form to all patients who 
were randomised without having the ability to consent at the 
time or a family member/guardian to consent on their behalf.
Trial Organisation
The TREC-Lebanon Co-ordinating Group: The co-ordinating 
centre of the Lebanese arm is based at the Institute of 
Mental Health, University of Nottingham, United Kingdom. The 
Co-ordinating Group has overall responsibility for the design of 
the proposed trial and is responsible for all aspects of day-to-day 
trial administration. The Co-ordinating Group is also responsible 
for preparing reports for the Steering Committee. Membership: JD, 
CEA, SH.
Steering Committee
The overall progress of the trial, adherence to protocol, patient 
safety and the consideration of new information will be moni-
tored by a scientific and administrative Steering Committee 
(SC). At the end of the proposed study period, the SC will 
consider the extension of the study, to allow the detection of 
other important effects. Membership: PS and RH.
Data Monitoring Committee
TREC-Lebanon will include a committee to oversee progress 
of the trial. Since TREC-Lebanon might take three to six 
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months to complete, an independent Data Monitoring Commit-
tee (DMC) will, in confidence, monitor results. This could be 
undertaken on a week to week or month to month basis depend-
ing on the collective agreement of all the members of the 
DMC. In the light of the interim data, and of any other evidence 
or advice they wish to seek, the DMC will inform the chair 
of the SC if, in their view: i) there is proof beyond reasonable 
doubt that for any particular group or subgroup treatment with 
one or other regiment is clearly indicated or contraindicated; 
or, ii) it is evident that no clear outcome will be obtained. 
Proof beyond reasonable doubt may be taken as the differ-
ence of at least three standard deviations and at least one of the 
primary outcomes.
The DMC may communicate certain interim analysis to the 
SC or suggest certain protocol changes, but the SC will remain 
responsible for deciding which changes to adopt. Member-
ship: GA and JM. The committee will receive the first batch 
of data when trial participants are at a total of 50 along with 
information such as adverse effects, unforeseen circumstances 
and trial progress so far.
Current Study Status
At the time of submission of this manuscript, trial was still 
ongoing albeit approaching its final phase. Presently, trial has 
concluded recruitment process. Data has been transcribed and 
awaiting analysis.
Dissemination of Study Outcomes
The results of TREC-Lebanon will be published in at least one 
peer reviewed indexed journal and will be presented in relevant 
conferences.
Discussion
As mentioned earlier, violence in the psychiatry setting is 
common and rapid tranquilisation is sometimes necessary and 
unavoidable. Not only are national guideline recommendations 
limited in their evidence backing - but surveys of practice have 
shown to differ from clinicians’ opinions on management during 
an agitated episode13.
The HP and HPC combination have both been used in rou-
tine care outside Lebanese practice16, but as far as systematic 
searching has shown, there exists no clinical trials randomising 
the HPC combination, making it an ideal candidate for 
randomisation.
Possible limitations for this trial are that there are no ERs; 
therefore residents must always carry the TREC envelopes at 
all times, increasing the risk for error (i.e. misplacing enve-
lope, using wrong envelope, etc.). Despite the limitation, the 
chances of error remain low due to the small sample size of 100.
Overall, since TREC-Lebanon is comparing two interventions 
with drug combinations that are used in its routine practice13, we 
assume in both cases that rapid tranquilisation will be achieved 
reducing the risk of the agitated patients harming themselves, as 
well as harming others.
Data availability
Underlying data
No underlying data is associated with this article.
Extended data
Open Science Framework: TREC-Lebanon Protocol, https://doi.
org/10.17605/OSF.IO/MYCQ946.
This project contains the following extended data:
-   TREC-Lebanon information for relatives
-   TREC-Envelope entry form
-   Primary measures of outcome form
-   Dr. Stopwatch form
-   TREC-Lebanon main data collection form
-   Dummy statistical tables
-   Serious event form
-   TREC-Lebanon consent form for patients
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
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